Skip to content

A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent

A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01252914
Enrollment
80
Registered
2010-12-03
Start date
2010-12-31
Completion date
2019-12-16
Last updated
2022-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subject With Primary Open-angle Glaucoma (POAG)

Keywords

Open angle, Glaucoma, Surgery, Ocular Hypertension, Eye Diseases

Brief summary

The purpose of this study is to assess the efficacy and safety of one iStent supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma.

Detailed description

The study assesses the efficacy and safety of one iStent supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma.

Interventions

DEVICEiStent Supra Stent

Implantation of one iStent Supra Stent through a small temporal clear corneal incision

Sponsors

Glaukos Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Diagnosed with primary open-angle glaucoma (POAG) * Subjects on two topical hypotensive medications

Exclusion criteria

* Traumatic, uveitic, neovascular, or angle closure glaucoma * Fellow eye already enrolled

Design outcomes

Primary

MeasureTime frame
Mean diurnal Intraocular Pressure reduction of greater than or equal to 20% at month 12 vs. baseline12 months

Secondary

MeasureTime frame
Mean diurnal Intraocular Pressure < 18 mmHg at month 1212 months

Other

MeasureTime frameDescription
Safety0-61 monthsRate of ocular adverse events through 61 months * Findings from Intraocular Pressure, best corrected visual acuity, visual field, specular microscopy measurements * Findings from slit-lamp, fundus and gonioscopic examinations

Countries

Armenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026